Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen and Epigenomics Pen Licensing, OEM Deal for DNA Methylation Analysis

NEW YORK, May 3 (GenomeWeb News) - Qiagen and Epigenomics have signed a licensing and OEM deal to develop products to analyze DNA methylation, the companies said today.


Under the agreement, Venlo, the Netherlands-based Qiagen exclusively licensed Epigenomics' bisulfite DNA treatment technology as well as its MethyLight assay technology to develop products for research purposes. In exchange, Berlin-based Epigenomics will receive up-front technology access and licensing fees, as well as royalties on the sales of research products.


For diagnostic purposes, Qiagen will market and sell products containing the bisulfite technology for use with Epigenomics' technologies and products. Under an OEM agreement, Qiagen will also provide Epigenomics with kit components for molecular diagnostic products.


All products developed under the agreement will be co-branded, and the first products are expected in 2006.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.